Estrogen therapy tied to lower Alzheimer’s risk in study

What happened: a new look at hormone therapy and Alzheimer’s

A Stanford Medicine team reported that women using estrogen-only menopausal hormone therapy (MHT) had a lower risk of Alzheimer’s disease outcomes than women who did not use any menopausal hormone therapy.

The findings were published Aug. 12, 2026, in Neurology and were highlighted Aug. 13, 2026, in a report from Stanford University.

The authors frame the work as a counterpoint to earlier studies that indicated menopausal hormone therapy raises dementia risk, arguing that their approach captures Alzheimer’s disease more directly.

• Study lead quote: “Our study is unique in that we looked at all the standards of Alzheimer’s diagnosis, including the gold-standard outcome: Alzheimer’s-associated hallmarks in autopsied brains,” said Hadi Hosseini, Ph.D.
• Co-author quote: “MHT appears to exert a modest but meaningful and statistically significant protective effect on the risk of developing Alzheimer’s pathology,” said Jennifer Bruno, Ph.D.

What the evidence actually shows about estrogen therapy and Alzheimer’s risk

The study is an analysis of existing databases that included postmortem brain findings, along with evidence from clinical diagnoses and cognitive and functional measures in living participants.

Across two databases totaling 21,462 participants, the investigators focused on deceased women whose brains were autopsied for two defining Alzheimer’s pathological features: amyloid plaques and neurofibrillary tangles, plus a third measure, the density of individual amyloid plaques.

In 258 autopsies from women who reported estrogen-only MHT use, compared with about 2,701 autopsies from women reporting no use of any form of menopausal hormone therapy, estrogen-only MHT use was associated with a statistically significant decrease in Alzheimer’s-related hallmarks. Using odds ratios, the team reported a 35% reduction in the odds of developing Alzheimer’s disease among estrogen-only MHT users, and estrogen-only MHT users had 39% lower odds than nonusers of receiving a clinical diagnosis of dementia during their lifetimes.

• Autopsy outcomes assessed: amyloid plaques, neurofibrillary tangles, and amyloid plaque density
• Reported association size: 35% reduction in odds of developing Alzheimer’s disease among estrogen-only MHT users (odds ratio)
• Clinical outcome reported: 39% lower odds of a lifetime dementia diagnosis among estrogen-only MHT users vs nonusers
• Other reported outcomes: better performance on memory tests and better overall ability to function independently among estrogen-only MHT users

Who it applies to: estrogen-only MHT users, often after hysterectomy

The findings specifically center on estrogen-only menopausal hormone therapy, which is generally prescribed for women without a uterus, meaning many users presumably had hysterectomies.

The women represented in the analysis skewed older, with an average age of 70, and many had had hysterectomies, so most were on estrogen-only regimens.

The researchers report adjusting for age, the APOE4 genetic variant, and a history of hypertension, as well as education and race, and they note the hormone-therapy association was smaller than well-known drivers such as age, APOE4, or hypertension history.

• Context figure reported: by age 60, more than 30% of women have had hysterectomies and no longer have a uterus
• Why this matters for applicability: estrogen-only treatment is specifically recommended for women without a uterus
• Key comparison from authors: the association is “modest” relative to age, APOE4, and hypertension history

Practical context for metabolic health readers

For readers focused on metabolic health, the study highlights that Alzheimer’s risk discussions may intersect with cardiovascular and metabolic risk factors that are also tied to cognitive outcomes, such as hypertension, which the researchers specifically adjusted for in their analyses.

The authors also emphasize a clinical reality that matters for prevention-focused care: memory problems have many causes, and clinical dementia diagnoses can be imperfect, which is why they prioritized “gold-standard” autopsy hallmarks and also considered biomarkers from cerebrospinal fluid and blood samples in living participants.

If you are considering menopausal hormone therapy for menopause-related reasons, this study provides evidence that estrogen-only MHT use was linked with lower odds of Alzheimer’s pathology and dementia diagnosis in the populations examined; however, decisions about hormone therapy still need to weigh overall risks and benefits with a clinician.

• What makes this report different: it connects estrogen-only MHT to Alzheimer’s hallmarks seen directly in brain tissue after death
• Metabolic overlap named in the study: hypertension was accounted for, and the authors note it has a larger effect than hormone therapy
• Outcome breadth: pathology at autopsy plus clinical diagnosis, memory testing, and ability to function independently

Limitations and caveats to keep in mind

This study reports associations rather than proving that estrogen-only menopausal hormone therapy prevents Alzheimer’s disease, even though it uses strong outcome measures such as autopsy findings.

The results are most directly relevant to estrogen-only therapy users, who are often women without a uterus, and the sample skewed older, with an average age of 70, so readers should be cautious about extending the findings to other hormone formulations or different groups not described in the report.

The authors also note that the protective association is not as strong as major risk factors such as age, APOE4, or hypertension history, which means hormone therapy, if used, would be one part of a larger risk picture rather than the dominant driver.

• Study scope: estrogen-only MHT, not “any MHT” in general
• Design caveat: observational database analysis with adjusted comparisons, not a randomized trial
• Effect-size context: smaller than age, APOE4, and hypertension history per the authors